MaxCyte, Inc. MXCT 深 滬
已收盤 02-06 16:00:00 美东时间
0.808
0.000
0.00%
華盛通- 最 高0.8606
- 今 開0.8118
- 成交量 174.63万股
- 最 低 0.7754
- 昨 收 0.808
- 總市值 8619.26万
- 52周最高 4.21
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 0.7473
- 委 比 -40.35%
- 總股本 1.07亿
- 歷史最高 17.44
- 量 比 0.88
- 振 幅 10.54%
- 歷史最低 0.7473
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell
01-12 21:18
MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026
MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
2025-11-13 05:17
MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same
2025-11-13 05:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance
MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue g
2025-11-05 21:24
MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Development
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today
2025-10-06 20:07
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte Inc. has signed a Strategic Platform License agreement with Moonlight Bio to support the development of T cell therapies using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. Moonlight Bio aims to improve outcomes for solid tumor treatments. MaxCyte will receive licensing fees and program-related revenue.
2025-10-06 12:05
MaxCyte Announces Major Workforce Reduction Plan
MaxCyte ( ($MXCT) ) has shared an announcement. On September 22, 2025, MaxCyte,...
2025-09-23 04:59
MaxCyte announces 34% workforce reduction to cut costs
MaxCyte (NASDAQ:MXCT) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel. The move is aimed at cutting operating expenses, streamlining...
2025-09-23 04:36
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings
MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
2025-09-23 04:33
